Mission Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $290K | Buy |
2,205
+29
| +1% | +$3.85K | 0.01% | 617 |
|
|
2025
Q4 | $309K | Buy |
2,176
+192
| +10% | +$27.8K | 0.01% | 608 |
|
|
2025
Q3 | $279K | Buy |
1,984
+69
| +4% | +$9.35K | 0.01% | 609 |
|
|
2025
Q2 | $241K | Sell |
1,915
-295
| -13% | -$33.8K | 0.01% | 617 |
|
|
2025
Q1 | $244K | Buy |
2,210
+400
| +22% | +$50.7K | 0.01% | 597 |
|
|
2024
Q4 | $247K | Buy |
+1,810
| New | +$224K | 0.01% | 580 |
|
|
2024
Q3 | – | Sell |
-1,725
| Closed | -$237K | – | 705 |
|
|
2024
Q2 | $237K | Hold |
1,725
| – | – | 0.01% | 577 |
|
|
2024
Q1 | $238K | Sell |
1,725
-75
| -4% | -$10.2K | 0.01% | 600 |
|
|
2023
Q4 | $237K | Sell |
1,800
-1,525
| -46% | -$176K | 0.01% | 520 |
|
|
2023
Q3 | $374K | Hold |
3,325
| – | – | 0.01% | 402 |
|
|
2023
Q2 | $314K | Hold |
3,325
| – | – | 0.01% | 446 |
|
|
2023
Q1 | $337K | Hold |
3,325
| – | – | 0.01% | 420 |
|
|
2022
Q4 | $397K | Buy |
3,325
+10
| +0.3% | +$1.17K | 0.02% | 369 |
|
|
2022
Q3 | $352K | Hold |
3,315
| – | – | 0.02% | 359 |
|
|
2022
Q2 | $323K | Hold |
3,315
| – | – | 0.02% | 381 |
|
|
2022
Q1 | $311K | Hold |
3,315
| – | – | 0.01% | 411 |
|
|
2021
Q4 | $282K | Hold |
3,315
| – | – | 0.01% | 449 |
|
|
2021
Q3 | $318K | Hold |
3,315
| – | – | 0.02% | 397 |
|
|
2021
Q2 | $323K | Hold |
3,315
| – | – | 0.02% | 378 |
|
|
2021
Q1 | $322K | Sell |
3,315
-1,204
| -27% | -$126K | 0.02% | 348 |
|
|
2020
Q4 | $433K | Hold |
4,519
| – | – | 0.03% | 268 |
|
|
2020
Q3 | $435K | Sell |
4,519
-1,205
| -21% | -$139K | 0.03% | 220 |
|
|
2020
Q2 | $698K | Buy |
5,724
+2,309
| +68% | +$255K | 0.06% | 151 |
|
|
2020
Q1 | $296K | Sell |
3,415
-12,045
| -78% | -$1.18M | 0.03% | 212 |
|
|
2019
Q4 | $1.66M | Buy |
15,460
+5,088
| +49% | +$533K | 0.16% | 83 |
|
|
2019
Q3 | $935K | Sell |
10,372
-2,500
| -19% | -$234K | 0.1% | 107 |
|
|
2019
Q2 | $1.09M | Sell |
12,872
-12,746
| -50% | -$1.05M | 0.12% | 91 |
|
|
2019
Q1 | $2.26M | Buy |
25,618
+12,784
| +100% | +$1.07M | 0.26% | 59 |
|
|
2018
Q4 | $916K | Buy |
+12,834
| New | +$1.23M | 0.12% | 96 |
|
|
2018
Q2 | – | Sell |
-2,625
| Closed | -$218K | – | 276 |
|
|
2018
Q1 | $218K | Hold |
2,625
| – | – | 0.04% | 209 |
|
|
2017
Q4 | $204K | Buy |
+2,625
| New | +$179K | 0.03% | 212 |
|
Other funds holding NBIX
VPM
VCM
Mission Wealth Management's NBIX Position: Q1 2026 in Review
Mission Wealth Management increased its Neurocrine Biosciences (NBIX) stake by 1.3% in Q1 2026, buying an estimated $3.85K and bringing the position to 2,205 shares worth $290K. The position accounts for 0.01% of the portfolio, ranked #617.
Mission Wealth Management first reported a position in NBIX in Q4 2017 and has held it in 31 quarters since. The position peaked at $2.26M in Q1 2019. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Mission Wealth Management held 2,205 shares of Neurocrine Biosciences worth $290K as of Q1 2026.
- Mission Wealth Management bought 29 Neurocrine Biosciences shares in Q1 2026, an estimated $3.85K.
- Neurocrine Biosciences made up 0.01% of Mission Wealth Management's portfolio in Q1 2026, its #617 holding.
- Mission Wealth Management first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 31 quarters since.
- Mission Wealth Management's Neurocrine Biosciences position peaked at $2.26M in Q1 2019.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Mission Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.